Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 541

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

Edeline, Julien, Benabdelghani, Meher, Bertaut, Aurélie, Watelet, Jérôme, Hammel, Pascal, Joly, Jean-Paul, Boudjema, Karim, Fartoux, Laetitia, Bouhier-Leporrier, Karine, Jouve, Jean-Louis, Faroux, Roger, Guerin-Meyer, Véronique, Kurtz, Jean-Emmanuel, Assénat, Eric, Seitz, Jean-François, Baumgaertner, Isabelle, Tougeron, David, de la Fouchardière, Christelle, Lombard-Bohas, Catherine, Boucher, Eveline, Stanbury, Trevor, Louvet, Christophe, Malka, David, Phelip, Jean-Marc·2019·Journal of Clinical Oncology

Abstract

PURPOSE: No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether gemcitabine and oxaliplatin chemotherapy (GEMOX) would increase relapse-free survival (RFS) while maintaining health-related quality of life (HRQOL) in patients who undergo resection. PATIENTS AND METHODS: We performed a multicenter, open-label, randomized phase III trial in 33 centers. Patients were randomly assigned (1:1) within 3 months after R0 or R1 resection of a localized BTC to receive either GEMOX (gemcitabine 1,000 mg/m 2 on day 1 and oxaliplatin 85 mg/m 2 infused on day 2 of a 2-week cycle) for 12 cycles (experimental arm A) or surveillance (standard arm B). Primary end points were RFS and HRQOL. RESULTS: Between July 2009 and February 2014, 196 patients were included. Baseline characteristics were balanced between the two arms. After a median follow-up of 46.5 months (95% CI, 42.6 to 49.3 months), 126 RFS events and 82 deaths were recorded. There was no significant difference in RFS between the two arms (median, 30.4 months in arm A v 18.5 months in arm B; hazard ratio [HR], 0.88; 95% CI, 0.62 to 1.25; P = .48). There was no difference in time to definitive deterioration of global HRQOL (median, 31.8 months in arm A v 32.1 months in arm B; HR, 1.28; 95% CI, 0.73 to 2.26; log-rank P = .39). Overall survival was not different (median, 75.8 months in arm A v 50.8 months in arm B; HR, 1.08; 95% CI, 0.70 to 1.66; log-rank P = .74). Maximal adverse events were grade 3 in 62% (arm A) versus 18% (arm B) and grade 4 in 11% versus 3% ( P < .001). CONCLUSION: There was no benefit of adjuvant GEMOX in resected BTC despite adequate tolerance and delivery of the regimen.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.00050

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 541

Metadata

Authors
Edeline, J., Benabdelghani, M., Bertaut, A., Watelet, J., Hammel, P., Joly, J.-P., Boudjema, K., Fartoux, L., Bouhier-Leporrier, K., Jouve, J.-L., Faroux, R., Guerin-Meyer, V., Kurtz, J.-E., Assénat, E., Seitz, J.-F., Baumgaertner, I., Tougeron, D., de la Fouchardière, C., Lombard-Bohas, C., Boucher, E., Stanbury, T., Louvet, C., Malka, D., & Phelip, J.-M.
Venue
Journal of Clinical Oncology
Published
2019-03-10
Volume
37
Issue
8
Pages
658-667
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2914858130
Cited by
541
References
17
FWCI
58.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. https://app.cochat.ai/papers/10.1200/jco.18.00050
The paper
Edeline, J., Benabdelghani, M., Bertaut, A., Watelet, J., Hammel, P., Joly, J.-P., Boudjema, K., Fartoux, L., Bouhier-Leporrier, K., Jouve, J.-L., Faroux, R., Guerin-Meyer, V., Kurtz, J.-E., Assénat, E., Seitz, J.-F., Baumgaertner, I., Tougeron, D., de la Fouchardière, C., Lombard-Bohas, C., . . . Phelip, J.-M. (2019). Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.00050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.